- GSK is acquiring lung cancer biotech Nuvalent in its biggest deal in over a decade Quartz —
- Quant rating check: Top oncology peers as Nuvalent goes private in $10.6B deal with GSK Seeking Alpha —
- GSK agrees to buy US cancer drug firm Nuvalent in £8bn deal Yorkshire Post —
- GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down MarketWatch —
- GSK to buy US cancer treatment firm Nuvalent for $10.6bn The Guardian —
- GSK Agrees to Buy Nuvalent for $10.6 Billion Bloomberg —
- GSK to buy US lung cancer drug specialist Nuvalent for £8bn The Argus —
- GSK to buy US lung cancer drug specialist Nuvalent for £8bn The Standard —
- GSK to buy US lung cancer drug specialist Nuvalent for £8bn The Independent —
- GSK to buy Nuvalent for $10.6B Seeking Alpha —
- GSK boosts cancer portfolio with $10.6bn Nuvalent deal RTE —
- GSK to buy US lung cancer drug specialist Nuvalent for £8bn LBC —
- GSK to buy US lung cancer drug specialist Nuvalent for £8bn The Standard —
- GSK to buy US lung cancer drug specialist Nuvalent for £8bn The Independent —
- GSK to buy US lung cancer drug specialist Nuvalent for £8bn Belfast Telegraph —
- GSK to Buy Nuvalent for $10.6 Billion in Oncology Push Wall Street Journal —
- GSK snaps up US cancer treatment firm Nuvalent in $10.6bn deal City AM —
- GSK boosts cancer portfolio with $10.6 billion Nuvalent takeover - Reuters Reuters —
- GSK in talks to buy Nuvalent for over $9B - report Seeking Alpha —
- GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT CNBC —
Nuvalent, Inc. (United States)
Company in Cambridge, United States
Also known as...
Nuvalent and Nuvalent, Inc.
GSK Acquires Nuvalent for $10.6 Billion